What are the recommended dosing, contraindications, and safety monitoring for daridorexant in adults with chronic insomnia?

Daridorexant Dosing and Safety Recommendations

For adults with chronic insomnia, prescribe daridorexant 50 mg once nightly, taken within 30 minutes of bedtime with at least 7 hours remaining before planned awakening, as this dose provides superior efficacy for both nighttime sleep and daytime functioning without increased adverse events compared to lower doses. 1

Recommended Dosing

Standard Dose:

• 25-50 mg once nightly is the FDA-approved range 1
• 50 mg is the preferred dose based on dose-response analyses showing linear efficacy improvements across all endpoints (wake after sleep onset, sleep latency, total sleep time, and daytime functioning) without dose-dependent increases in adverse events 2
• Take within 30 minutes before bedtime with ≥7 hours remaining before planned awakening 1
• Avoid taking with or soon after meals as this delays sleep onset 1

Special Populations:

• Elderly (≥65 years): No dose adjustment needed; 50 mg remains the optimal dose for improving both sleep and daytime functioning in older adults 1, 3
• Moderate hepatic impairment (Child-Pugh 7-9): Maximum 25 mg once nightly due to increased drug exposure 1
• Severe hepatic impairment (Child-Pugh ≥10): Not recommended 1
• Renal impairment: No specific dose adjustments mentioned in labeling 1

Absolute Contraindications

Do not prescribe daridorexant in patients with:

• Narcolepsy 1
• Known hypersensitivity to daridorexant or any component 1

Drug Interactions Requiring Dose Modification

Avoid concomitant use with:

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) 1
• Moderate or strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) 1

Reduce dose to maximum 25 mg with:

• Moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin, fluconazole) 1

Critical Safety Warnings

CNS Depression and Next-Day Impairment

• Warn patients against next-day driving and activities requiring complete mental alertness until they know how daridorexant affects them 1
• Risk increases when combined with other CNS depressants (alcohol, opioids, benzodiazepines) 1
• Morning impairment can occur even with proper timing 1

Complex Sleep Behaviors

• Discontinue immediately if complex sleep behaviors occur (sleepwalking, sleep-driving, engaging in activities while not fully awake) 1
• These can occur after the first dose or at any time during treatment 1

Psychiatric Effects

• Monitor for worsening depression or suicidal ideation 1
• Reevaluate if insomnia persists after 7-10 days to identify underlying psychiatric or medical conditions 1

Narcolepsy-Like Symptoms

• Sleep paralysis, hypnagogic/hypnopompic hallucinations, and cataplexy-like symptoms may occur 1
• These are mechanism-related effects of orexin receptor antagonism 1

Respiratory Considerations

• Use caution in patients with compromised respiratory function 1
• Studies in mild-to-moderate OSA and moderate COPD showed minimal respiratory effects, but clinically meaningful effects cannot be excluded, especially with long-term use 1
• Severe OSA or severe COPD patients were not studied—exercise clinical judgment 1

Safety Monitoring

Baseline Assessment:

• Screen for narcolepsy symptoms
• Assess for sleep apnea and respiratory disorders
• Evaluate for depression/suicidal ideation
• Review all CNS-active medications and alcohol use
• Liver function tests if hepatic impairment suspected

Ongoing Monitoring:

• Falls risk, particularly in elderly patients (daridorexant increases somnolence/drowsiness with age) 1
• Next-morning residual effects and daytime functioning
• Emergence of complex sleep behaviors
• Worsening depression or suicidal thoughts
• No withdrawal symptoms or rebound insomnia observed after discontinuation—no tapering required 4

Special Populations

Pregnancy/Lactation:

• Daridorexant is present in breast milk at low levels (relative infant dose <1% of maternal dose) 1
• Monitor breastfed infants for excessive sedation 1
• Weigh benefits of breastfeeding against maternal need for treatment 1

Pediatric:

• Safety and efficacy not established in children 1

Efficacy Timeline

• Improvements begin within 1 week and are sustained through 12 months of treatment 4, 5
• At 50 mg, daridorexant reduces wake after sleep onset by ~20 minutes and increases total sleep time by ~20 minutes compared to placebo at 3 months 5
• Daytime functioning improvements are dose-dependent and most pronounced with 50 mg 5, 3

Common Adverse Events

• Headache and somnolence/fatigue are most common (≥5% and greater than placebo) 1
• Overall adverse event incidence similar to placebo (35-40%) 1, 4
• No dose-dependent increase in adverse events including somnolence/fatigue 2
• Nasopharyngitis and headache most frequently reported across all doses 5

Controlled Substance Status

• Schedule IV controlled substance 1
• Abuse potential lower than zolpidem at therapeutic doses but present at supratherapeutic doses 1

Key Clinical Pearls

• 50 mg provides maximal benefit for both sleep and daytime functioning without increased safety concerns 2, 5, 3
• Unlike some hypnotics, daridorexant maintains efficacy throughout the entire night (all quarters of sleep) 6
• No correlation between nighttime wake reduction and next-day sleepiness—improvements in daytime functioning occur independently 6
• Long-term use (up to 12 months) shows sustained efficacy without new safety signals 4